Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties

Hattesohl, Miguel; Feistel, Björn; Sievers, Hartwig; Lehnfeld, Romanus; Hegger, Mirjam; Winterhoff, Hilke

doi:10.1016/j.phymed.2007.11.027

« Previous Next »Phytomedicine
Volume 15, Issue 1 , Pages 2-15, 25 January 2008

Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties

Miguel Hattesohl
- Department of Pharmacology and Toxicology, Universitätsklinikum Münster, Westfälische Wilhelms-Universität Münster, Domagkstr. 12, 48149 Münster, Germany
- Corresponding author. Tel.:+492518355514; fax: +492518355501.
Björn Feistel
- Finzelberg GmbH & Co. KG, Koblenzer Str. 48-56, 56626 Andernach, Germany
Hartwig Sievers
- PhytoLab GmbH & Co. KG, Dutendorfer Str. 5-7, 91487 Vestenbergsgreuth, Germany
Romanus Lehnfeld
- PhytoLab GmbH & Co. KG, Dutendorfer Str. 5-7, 91487 Vestenbergsgreuth, Germany
Mirjam Hegger
- Department of Pharmacology and Toxicology, Universitätsklinikum Münster, Westfälische Wilhelms-Universität Münster, Domagkstr. 12, 48149 Münster, Germany
Hilke Winterhoff
- Department of Pharmacology and Toxicology, Universitätsklinikum Münster, Westfälische Wilhelms-Universität Münster, Domagkstr. 12, 48149 Münster, Germany

Abstract

Extracts of Valeriana officinalis L. s.l. are used for treating mild sleep disorders and nervous tension. Despite intensive research efforts, the pharmacological actions accounting for the clinical efficacy of valerian remain unclear. Thus, it was the aim of this study to evaluate CNS-related effects of different valerian extracts using behavioral paradigms (mice and rats). Following oral administration two commercially available preparations (extraction solvents: 45% methanol m/m and 70% ethanol v/v), a 35% ethanolic v/v extract and a refined extract derived from it (patented special extract phytofin Valerian 368) were tested for sedative (locomotor activity, ether-induced anaesthesia) and anxiolytic (elevated plus maze) activity. Using the forced swimming and the horizontal wire test the latter two extracts were additionally tested for antidepressant and myorelaxant properties.

Up to maximum dosages of 500 or 1000mg/kg bw none of the valerian extracts displayed sedative effects. Neither spontaneous activity was reduced nor the duration of ether-induced narcosis was prolonged. In contrast, results obtained in the elevated plus maze test revealed a pronounced anxiolytic effect of the 45% methanolic and 35% ethanolic extract as well as of phyotofin Valerian 368 in a dose range of 100–500mg/kg bw. Additionally and different from its primary extract (35% ethanolic extract) phytofin Valerian 368 showed antidepressant activity in the forced swimming test after subacute treatment. Myorelaxant effects were not observed in dosages up to 1000mg/kg bw.

Due to these findings it is proposed that not sedative but anxiolytic and antidepressant activity, which was elaborated particularly in the special extract phytofin Valerian 368, considerably contribute to the sleep-enhancing properties of valerian.

Keywords: Valeriana officinalis L.s.l., Elevated plus maze, Anxiolytic, Sedative, Locomotor activity, Antidepressant, Myorelaxant